Publications by authors named "Anais Ollivier"

Although the effects of cigarette smoke (CS) on the development of several intestinal diseases is well documented, the impact of e-cigarette aerosol (e-cig) on digestive health is largely unknown. To compare the effects of e-cig and CS on mouse ileum and colon, animals were chronically exposed for 6 months by nose-only inhalation to e-cig at 18 or 30 W power, or to 3R4F CS. Results showed that e-cig exposure decreased colon cell proliferation.

View Article and Find Full Text PDF

(1) Background: viral infections are a frequent cause of chronic obstructive pulmonary disease (COPD) exacerbations, which are responsible for disease progression and mortality. Previous reports showed that IL-20 cytokines facilitate bacterial lung infection, but their production and their role in COPD and viral infection has not yet been investigated. (2) Methods: C57BL/6 WT and IL-20 Rb KO mice were chronically exposed to air or cigarette smoke (CS) to mimic COPD.

View Article and Find Full Text PDF

Tobacco smoking is classified as a human carcinogen. A wide variety of new products, in particular electronic cigarettes (e-cigs), have recently appeared on the market as an alternative to smoking. Although the in vitro toxicity of e-cigs is relatively well known, there is currently a lack of data on their long-term health effects.

View Article and Find Full Text PDF

Hepatitis B virus (HBV) infection and bile acid (BA) metabolism are interdependent: infection modifies the expression of the BA nuclear receptor farnesoid X receptor (FXR)-α, and modulation of FXRα activity by ligands alters HBV replication. Mechanisms of HBV control by FXRα remain to be unveiled. FXRα silencing in HBV-infected HepaRG cells decreased the viral covalently closed circular (ccc)DNA pool size and transcriptional activity.

View Article and Find Full Text PDF
Article Synopsis
  • Current hepatitis B therapies lower viral levels but don't eliminate the virus, prompting research into immune-modulating treatments.
  • The study examined the effects of various Toll-Like-Receptor (TLR) agonists on HBV-infected liver cells, finding that Pam3CSK4 and poly(I:C)-(HMW) were most effective at reducing viral indicators.
  • The results suggest that activating innate immunity through TLR agonists may offer a new approach to directly control HBV replication, supporting further development of TLR-based antiviral therapies.
View Article and Find Full Text PDF